Trials / Completed
CompletedNCT00002200
A Study of 1592U89 in HIV-Infected Adults
A 1592U89 Open-Label Protocol for Adult Patients With HIV-1 Infection.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Glaxo Wellcome · Industry
- Sex
- All
- Age
- 13 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see if it is safe and effective to give 1592U89 to HIV-positive adults. This study also examines the influence previous anti-HIV treatment has on the effectiveness of 1592U89.
Detailed description
Patients receive open-label 1592U89 administered orally in combination with at least one other antiretroviral agent that the patient has not previously received.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Abacavir sulfate |
Timeline
- First posted
- 2001-08-31
- Last updated
- 2005-06-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00002200. Inclusion in this directory is not an endorsement.